Biotech’s Catch-22, $100 genome, & monkeypox response

[ad_1]

Will gene therapy ever live up to expectations? Can anyone break up the genomics monopoly? And is innovation actually bad for biotech?

We cover all that and more this week on “The Readout LOUD,” STAT’s biotech podcast. Health care strategist Jared Holz of Oppenheimer joins us to discuss the weekend’s big oncology conference and what it will take to change Wall Street’s dire view of the drug industry. We also discuss a weighty FDA meeting on gene therapy, the potential of a $100 genome, and how the expanding monkeypox outbreak is creating challenges for public health agencies.

For more on what we cover, here’s the latest on cheap genomics; here’s more on monkeypox; here’s an update on biotech malaise; here’s where you can find episodes of Color Code; here’s where you can subscribe to the First Opinion Podcast; and here’s our complete coverage of the Covid-19 pandemic.

advertisement

Be sure to sign up on Apple Podcasts, Spotify, StitcherGoogle Play, or wherever you get your podcasts.

And if you have any feedback for us — topics to cover, guests to invite, vocal tics to cease — you can email [email protected].



[ad_2]

Source link

AsadKhan92

Learn More →

Leave a Reply

Your email address will not be published.